Skip to main content
. 2015 Sep 14;125(10):3819–3830. doi: 10.1172/JCI79048

Figure 6. Administration of perhexiline increased HDL-C and ApoA-I levels and enhanced serum cholesterol efflux capacity in Apoe–/– mice.

Figure 6

Apoe–/– mice were placed on a HFD for 12 weeks and then were treated with DMSO or perhexiline at 10 mg/kg for 6 weeks (3 times a week) via gavage administration with continuous HFD (n = 15 per group). Plasma samples were collected and subjected individually to analytical chemistry to measure HDL-C (A), TC (B), LDL-C (C), and TG (D). *P < 0.05, Student’s t test. (E) The ABCA1-mediated cholesterol efflux capacity of serum from DMSO- or perhexiline-treated mice is expressed as the percentage of cholesterol efflux of total cell cholesterol (n = 15 per group). *P < 0.05, Student’s t test. The pooled serum from DMSO- or perhexiline-treated mice was analyzed by HPLC (fractions 1 to 32) and the cholesterol (F) and TG (G) levels in each fraction were measured. (H) Representative Western blot and quantifications of ApoA-I levels by Western blot analysis in 3 μl of plasma samples from mice treated with DMSO or perhexiline (n = 14 per group). *P < 0.05, Student’s t test. Values represent mean ± SEM.